Furthermore, Ruxolitinib, a JAK2-specific inhibitor, is demonstrated to decrease the migration ability and phosphorylation of STAT3 in Rab3C-overexpressing CRC cells (Chang et al. 2017). Here, STAT3 is linked to colorectal carcinoma.